T
TherapeuticsMD Inc (TXMD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
$1.81
-0.06 (-3.21%)
Market Cap: $21.64M
Last updated: Nov 17, 2026 at 11:00 AM ET
TherapeuticsMD Inc (TXMD) Valuation Multiples
TherapeuticsMD (TXMD) trades at 5.6x sales and 0.8x book value. Its P/S of 5.6x is below its 10-year median of 11.2x. Its forward P/E is 2.3x.
Current Multiples
Its enterprise value is 5.7x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 2.3x |
| Price to sales | 5.6x |
| Price to book | 0.8x |
| EV/EBITDA | 5.7x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 5.6x | N/A | 11.2x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.3x in 2022 to 74.2x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $1.63 | 22.7x | 6.2x | 0.7x |
| 2024 | $0.86 | N/A | 5.6x | 0.4x |
| 2023 | $2.25 | N/A | 18.1x | 0.9x |
| 2022 | $5.59 | 0.5x | 1.3x | 124.9x |
| 2021 | $17.78 | N/A | 16.2x | N/A |
| 2020 | $60.50 | N/A | 5.2x | N/A |
| 2019 | $121.00 | N/A | 12.1x | 68.8x |
| 2018 | $190.50 | N/A | 53.4x | 9.3x |
| 2017 | $302.00 | N/A | 74.2x | 10.1x |
| 2016 | $288.50 | N/A | 58.4x | 8.9x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TXMD
What is TXMD's forward P/E ratio?
TherapeuticsMD has a forward P/E ratio of 2.3x.
Is TXMD stock overvalued?
GNG's valuation label for TXMD is Undervalued.
What is TXMD's price to sales ratio?
TherapeuticsMD has a price to sales ratio of 5.6x.
TXMD pages: Overview, Earnings, Financials, Valuation, Competitors